Comparison of Effects of Telmisartan and Valsartan on Late Lumen Loss and Inflammatory Markers After Sirolimus-Eluting Stent Implantation in Hypertensive Patients

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

We compared the effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. This was a prospective, randomized, single-blinded, 8-month follow-up study that included hypertensive patients with significant coronary artery stenosis treated with telmisartan (n = 79) or valsartan (n = 80). Risk factors such as diabetes, hyperlipidemia, smoking, and obesity were similar between groups. After 8 months of follow-up, only the telmisartan group showed significant decreases in interleukin-6 and tumor necrosis factor-α. The decreases from baseline level in total cholesterol and low-density lipoprotein cholesterol concentrations were significantly greater in the telmisartan group. The increase in adiponectin concentrations from baseline measurements was significantly greater in the telmisartan group than in the valsartan group (1.9 ± 2.7 vs 0.4 ± 2.0 μg/ml, respectively, p <0.05). Moreover, late lumen loss was significantly lower in the telmisartan group than in the valsartan group (0.1 ± 0.4 vs 0.3 ± 0.5 mm, respectively, p = 0.001). Major adverse cardiac events were similar between groups. In conclusion, compared with valsartan, telmisartan was associated with a significant decrease in late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients with significant coronary narrowing.

Original languageEnglish
Pages (from-to)1625-1629
Number of pages5
JournalAmerican Journal of Cardiology
Volume100
Issue number11
DOIs
Publication statusPublished - 2007 Dec 1

Fingerprint

Valsartan
Sirolimus
Stents
Coronary Stenosis
Adiponectin
telmisartan
Hyperlipidemias
LDL Cholesterol
Interleukin-6
Tumor Necrosis Factor-alpha
Obesity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{62d155a395e24bafb412238dbce69506,
title = "Comparison of Effects of Telmisartan and Valsartan on Late Lumen Loss and Inflammatory Markers After Sirolimus-Eluting Stent Implantation in Hypertensive Patients",
abstract = "We compared the effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. This was a prospective, randomized, single-blinded, 8-month follow-up study that included hypertensive patients with significant coronary artery stenosis treated with telmisartan (n = 79) or valsartan (n = 80). Risk factors such as diabetes, hyperlipidemia, smoking, and obesity were similar between groups. After 8 months of follow-up, only the telmisartan group showed significant decreases in interleukin-6 and tumor necrosis factor-α. The decreases from baseline level in total cholesterol and low-density lipoprotein cholesterol concentrations were significantly greater in the telmisartan group. The increase in adiponectin concentrations from baseline measurements was significantly greater in the telmisartan group than in the valsartan group (1.9 ± 2.7 vs 0.4 ± 2.0 μg/ml, respectively, p <0.05). Moreover, late lumen loss was significantly lower in the telmisartan group than in the valsartan group (0.1 ± 0.4 vs 0.3 ± 0.5 mm, respectively, p = 0.001). Major adverse cardiac events were similar between groups. In conclusion, compared with valsartan, telmisartan was associated with a significant decrease in late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients with significant coronary narrowing.",
author = "Hong, {Soon Jun} and Shim, {Wan Joo} and Jongil Choi and Joo, {Hyung Joon} and Shin, {Seung Yong} and Seong-Mi Park and Lim, {Sang Yeob} and Do-Sun Lim",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/j.amjcard.2007.06.068",
language = "English",
volume = "100",
pages = "1625--1629",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Comparison of Effects of Telmisartan and Valsartan on Late Lumen Loss and Inflammatory Markers After Sirolimus-Eluting Stent Implantation in Hypertensive Patients

AU - Hong, Soon Jun

AU - Shim, Wan Joo

AU - Choi, Jongil

AU - Joo, Hyung Joon

AU - Shin, Seung Yong

AU - Park, Seong-Mi

AU - Lim, Sang Yeob

AU - Lim, Do-Sun

PY - 2007/12/1

Y1 - 2007/12/1

N2 - We compared the effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. This was a prospective, randomized, single-blinded, 8-month follow-up study that included hypertensive patients with significant coronary artery stenosis treated with telmisartan (n = 79) or valsartan (n = 80). Risk factors such as diabetes, hyperlipidemia, smoking, and obesity were similar between groups. After 8 months of follow-up, only the telmisartan group showed significant decreases in interleukin-6 and tumor necrosis factor-α. The decreases from baseline level in total cholesterol and low-density lipoprotein cholesterol concentrations were significantly greater in the telmisartan group. The increase in adiponectin concentrations from baseline measurements was significantly greater in the telmisartan group than in the valsartan group (1.9 ± 2.7 vs 0.4 ± 2.0 μg/ml, respectively, p <0.05). Moreover, late lumen loss was significantly lower in the telmisartan group than in the valsartan group (0.1 ± 0.4 vs 0.3 ± 0.5 mm, respectively, p = 0.001). Major adverse cardiac events were similar between groups. In conclusion, compared with valsartan, telmisartan was associated with a significant decrease in late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients with significant coronary narrowing.

AB - We compared the effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. This was a prospective, randomized, single-blinded, 8-month follow-up study that included hypertensive patients with significant coronary artery stenosis treated with telmisartan (n = 79) or valsartan (n = 80). Risk factors such as diabetes, hyperlipidemia, smoking, and obesity were similar between groups. After 8 months of follow-up, only the telmisartan group showed significant decreases in interleukin-6 and tumor necrosis factor-α. The decreases from baseline level in total cholesterol and low-density lipoprotein cholesterol concentrations were significantly greater in the telmisartan group. The increase in adiponectin concentrations from baseline measurements was significantly greater in the telmisartan group than in the valsartan group (1.9 ± 2.7 vs 0.4 ± 2.0 μg/ml, respectively, p <0.05). Moreover, late lumen loss was significantly lower in the telmisartan group than in the valsartan group (0.1 ± 0.4 vs 0.3 ± 0.5 mm, respectively, p = 0.001). Major adverse cardiac events were similar between groups. In conclusion, compared with valsartan, telmisartan was associated with a significant decrease in late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients with significant coronary narrowing.

UR - http://www.scopus.com/inward/record.url?scp=36248953701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248953701&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2007.06.068

DO - 10.1016/j.amjcard.2007.06.068

M3 - Article

VL - 100

SP - 1625

EP - 1629

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 11

ER -